Effect of intravenous recombinant tissue-type plasminogen activator in patients with mild stroke in the third international stroke trial-3: Post hoc analysis

Stroke

Volumn 46, Issue 8, 2015, Pages 2325-2327

  Khatri, Pooja ^a   Tayama, Darren ^b   Cohen, Geoff ^c   Lindley, Richard I ^d   Wardlaw, Joanna M ^c   Yeatts, Sharon D ^e   Broderick, Joseph P ^a   Sandercock, Peter ^c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b GENENTECH INC   (United States)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF SYDNEY   (Australia)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Clinical trials; Stroke; Thrombolytic therapy

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

AGED; ARTICLE; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; PREMEDICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; TREATMENT OUTCOME; CLINICAL TRIAL; INTERNATIONAL COOPERATION; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; STROKE; VERY ELDERLY;

ADMINISTRATION, INTRAVENOUS; AGED; AGED, 80 AND OVER; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INTERNATIONALITY; MALE; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84944711375     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.009951     Document Type: Article

References (9)

1. Reeves M, Khoury J, Alwell K, Moomaw C, Flaherty M, Woo D, et al. Distribution of National Institutes of Health stroke scale in the Cincinnati/Northern Kentucky Stroke Study. Stroke. 2013;44:3211-3213. doi: 10.1161/STROKEAHA.113.002881.
2. Khatri P, Conaway MR, Johnston KC; Acute Stroke Accurate Prediction Study (ASAP) Investigators. Ninety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic stroke. Stroke. 2012;43:560-562. doi: 10.1161/STROKEAHA.110.593897.
3. Khatri P, Kleindorfer DO, Yeatts SD, Saver JL, Levine SR, Lyden PD, et al. Strokes with minor symptoms: an exploratory analysis of the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator trials. Stroke. 2010;41:2581-2586. doi: 10.1161/STROKEAHA.110.593632.
4. The IST-3 Collaborative Group. The Benefits and Harms of Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator within 6 h of Acute Ischaemic Stroke (the Third International Stroke Trial [IST-3]). Lancet. 2012;379:2352-2363.
5. ClinialTrials.gov. A Study of the Efficacy and Safety of Activase (Alteplase) in Patients With Mild Stroke (PRISMS). Identifier: NCT02072226. http://clinicaltrials.gov/ct2/show/NCT02072226?term=stroke+tPA+PRISMS& rank=1. Published February 24, 2014. Accessed October 6, 2014.
6. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:870-947. doi: 10.1161/STR.0b013e318284056a.
7. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695-1703. doi: 10.1016/S0140-6736(10)60491-6.
8. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al; Stroke Thrombolysis Trialists' Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384:1929-1935. doi: 10.1016/S0140-6736(14)60584-5.
9. Whiteley WN, Thompson D, Murray G, Cohen G, Lindley RI, Wardlaw J, et al; IST-3 Collaborative Group. Effect of alteplase within 6 hours of acute ischemic stroke on all-cause mortality (third International Stroke Trial). Stroke. 2014;45:3612-3617. doi: 10.1161/STROKEAHA.114.006890.